1227923-29-6Relevant articles and documents
MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate
Beshore, Douglas C.,Di Marco, Christina N.,Chang, Ronald K.,Greshock, Thomas J.,Ma, Lei,Wittmann, Marion,Seager, Matthew A.,Koeplinger, Kenneth A.,Thompson, Charles D.,Fuerst, Joy,Hartman, George D.,Bilodeau, Mark T.,Ray, William J.,Kuduk, Scott D.
, p. 652 - 656 (2018/05/14)
Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.
DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
Page/Page column 39, (2012/04/23)
The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease